Regarding the MRD, Camus et al. reported that the XPO1 E571K mutation may be used as a biomarker in classical HL, using digital PCR, because in their study, patients with a detectable XPO1 mutation at the end of treatment could have a shorter free progression survival, but the results were not statistically significant [135]. This evidence concerns the gene XPO1 and Hodgkins lymphoma.